Clinical Trials Logo
  1. Home
  2. Thyroid Eye Disease
  3. NCT06021054

A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)

Thyroid Eye Disease Clinical Trial

Official title:
A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)

Clinical Trial Summary

A randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001 in participants with chronic thyroid eye disease (TED)

Clinical Trial Description

A randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06021054
Study type Interventional
Source Viridian Therapeutics, Inc.
Contact
Status Recruiting
Phase Phase 3
Start date November 14, 2023
Completion date September 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04583735 - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease Phase 4
Active, not recruiting NCT05002998 - TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Phase 4
Withdrawn NCT02422368 - The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Phase 2/Phase 3
Completed NCT03298867 - Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Phase 3
Recruiting NCT05987423 - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease Phase 3
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT05517447 - Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Phase 3
Terminated NCT04737330 - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Phase 3
Recruiting NCT05517421 - Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Phase 3
Recruiting NCT04311606 - Anti-VEGF Therapy for Acute Thyroid Eye Disease Phase 2
Recruiting NCT06106828 - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2) Phase 3
Recruiting NCT06367517 - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrolling by invitation NCT05241626 - AS-OCT of the Cornea in Thyroid Diseases
Active, not recruiting NCT05776121 - Study of ZB001 in Chinese Patients With Thyroid Eye Disease Phase 1
Recruiting NCT04359979 - Tamsulosin for Thyroid Lid Retraction N/A
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Terminated NCT02845336 - Celecoxib for Thyroid Eye Disease Phase 2
Recruiting NCT06307626 - A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. Phase 3
Recruiting NCT06307613 - A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease Phase 3